胞巢型橫紋肌肉瘤 (ARMS) 治療的全球市場:2020年∼2027年
Global Alveolar Rhabdomyosarcoma Treatment Market - 2020-2027
|出版日期||內容資訊||英文 180 Pages
|胞巢型橫紋肌肉瘤 (ARMS) 治療的全球市場:2020年∼2027年 Global Alveolar Rhabdomyosarcoma Treatment Market - 2020-2027|
|出版日期: 2021年05月12日||內容資訊: 英文 180 Pages||
全球胞巢型橫紋肌肉瘤 (ARMS) 治療市場成長的主要因素有病例數的增加，技術的進步，政府和非政府的配合措施增加，進行中的幾個臨床試驗等。
本報告提供全球胞巢型橫紋肌肉瘤 (ARMS) 治療市場相關調查分析，提供產業分析，各市場區隔的市場分析，競爭情形，主要企業等相關的系統性資訊。
The Global Alveolar Rhabdomyosarcoma Treatment Market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Alveolar Rhabdomyosarcoma (ARMS) is one type of rhabdomyosarcoma, a soft tissue sarcoma that originates from the body's connective tissues such as bone, muscle, cartilage, and ligaments. ARMS is mainly detected in adolescents and often occurs on the arms, legs, chest, and stomach. The exact cause of alveolar rhabdomyosarcoma is unknown. However, it is associated with other conditions such as Neurofibromatosis type 1, Beckwith-Wiedemann syndrome, Li-Fraumeni syndrome, Cardio-facial-cutaneous syndrome, and Costello syndrome. The methods for diagnosis of ARMS include examination such as X-ray imaging, CT scan, MRI, bone scan, ultrasound, PET scan, and a biopsy to plan a suitable treatment for the condition. ARMS is a high-grade tumor, meaning its cells are characterized by rapid growth and faster progression. As per the Surveillance Epidemiology and End Results (SEER) database, ARMS constitutes 23% of patients among the types of RMS. Also, alveolar rhabdomyosarcoma needs more intensive therapy than embryonal rhabdomyosarcoma. Radiation therapy, including intensity-modulated radiotherapy (IMRT) and proton beam radiation therapy, are implemented as an effective way to shrink the tumor cells post-chemotherapy. Chemotherapy and radiation therapy are mainly used to shrink the tumor's size before surgery and minimize the risk of cancer reoccurrence post-surgery.
The global Alveolar Rhabdomyosarcoma Treatment market growth is driven by the growing prevalance of alveolar rhabdomyosarcoma cases, increasing technological advancements, growing government and non-government initiatives, several on-going clinical trials are the major factors driving the market.
Growing prevalance of Alveolar Rhabdomyosarcoma cases, is expected to drive the market during the forecast period.
The prevalence of rhabdomyosarcoma does not vary by sex and is static from ages 0 to 19 years, with approximately 1 case per 1 million children and adolescents. About 400 to 500 new cases of rhabdomyosarcoma (RMS) occur each year in the United States. This sub-type constitutes 23% of patients in the SEER database. These factors are driving the growth of the market in the forecast period.
Latest technologies in radiation therapy treatment, is expected to drive the market during the forecast period.
Stereotactic body radiation therapy (SBRT) is a unique machine that aims at very thin beams of radiation at the tumor from many different angles, concentrating it on the tumor very precisely for short periods.
Proton beam radiation is another newer approach. Proton beam radiation uses radioactive particles that travel only a certain distance before releasing most of their energy.
Major side effects of Treatments is likely to hinder the market growth.
Surgery short-term severe side effects are not common, but they can include reactions to anesthesia, excess bleeding, blood clots, and infections. Side effects common to many chemo drugs include Hair loss, mouth sores, loss of appetite, Nausea and vomiting, Diarrhea, Increased chance of infections, Easy bruising or bleeding, Fatigue.
Side effects of radiation therapy on the brain can include headaches and problems such as memory loss, personality changes.
COVID-19 Impact Analysis
The COVID-19 pandemic has negatively impacted healthcare systems globally and on the market growth. According to the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweighed the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the On-going clinical trials too. However, the situation is expected to improve gradually.
Based on Treatment method, the global Alveolar Rhabdomyosarcoma Treatment market is segmented into Surgery, Chemotherapy, Radiation Therapy.
Currently, Chemotherapy dominates the market and is anticipated to continue this trend throughout the forecasting period. The key factors driving the market growth include an increase in demand for chemotherapy drugs and also surgery cannot be done without these drugs. Chemotherapy is the use of drugs to treat cancer. Chemo is systemic therapy, meaning that the drugs enter the bloodstream and go throughout the body to destroy cancer cells. This makes chemo helpful in killing cancer cells that have spread to other parts of the body, even if they can't be seen. Chemo is an essential part of treatment for alveolar rhabdomyosarcoma (ARMS). In the low-risk groups, the main combinations of drugs used are vincristine and dactinomycin (also known as actinomycin-D) and cyclophosphamide.
In the intermediate-risk group, vincristine, dactinomycin, cyclophosphamide, and cyclophosphamide alternates with vincristine and irinotecan.
In high-risk groups, along with vincristine, doxorubicin, ifosfamide, and etoposide are also used.
For instance, A randomized Phase 3 clinical trials to Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate-Risk (IR) Rhabdomyosarcoma (RMS) by National Cancer Institute (NCI) is expected to completed by 2025 which increases the demand for this segment.
Based on End-User, the global Alveolar Rhabdomyosarcoma Treatment market is segmented into Hospitals, Cancer Research centers, Surgical centers, others.
Due to the growing patient population, the hospitals segment held the largest market share. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment. Also the medications can only be administrated by intravenously and surgery is done under supervision of medical practioners at these locations.
North America served the largest share of the global alveolar rhabdomyosarcoma treatment market over the forecast period, owing to the rising number of initiatives undertaken by organizations in the region to develop potential therapies, increasing research and development, and adoption of advanced radiation therapies. Organizations in the region have initiated the first molecular targeted drug in a clinical trial in 2011 for childhood muscle cancer at the Doernbecher Children's Hospital and Children Oncology Group (COG) sites. Also, St. Baldrick's Foundation collaborates with pediatric oncologists and funds supportive cancer research to develop promising research to impact the treatment of children with cancer positively. Moreover, other organizations such as the National Cancer Institute, Scott Carter Foundation, Alex's Lemonade Stand Foundation, and the Hyundai Hope on Wheels Program have funded various studies to explore high potential therapeutic options.
The Asia Pacific is expected to be the fastest-growing market over the forecast period owing to increasing prevalence rate, increasing focus on preventive care, and government initiatives promoting technological innovations. For instance, Eisai Inc- A Phase 2 clinical trial is undergoing to study the safety and preliminary activity of eribulin mesylate in pediatric participants with relapsed/refractory rhabdomyosarcoma (RMS).
The global Alveolar Rhabdomyosarcoma Treatment market is quite competitive with some key competitors like Eli Lilly and Company, GlaxoSmithKline Plc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb, F. Hoffmann-La Roche AG, Oasmia Pharmaceutical, Celgene Corporation, Pfizer, Inc., and Johnson & Johnson Services, Inc, Eisai Inc. The key players are adopting various growth strategies such as product launch, acquisitions and investments in multiple sectors.
For instance, according to clinicaltrials.gov; A Phase I/II Trial of the Insulin-Like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination with the Src Family Kinase (SFK) Inhibitor Dasatinib in Patients with Embryonal and Alveolar Rhabdomyosarcoma is conducting by the National Institutes of Health Clinical Center (CC) and National Cancer Institute (NCI) is expected to complete by 2022.
Boehringer Ingelheim GmbH
Overview: Boehringer Ingelheim was the pharmaceutical company founded in 1885 by Albert Boehringer (1861-1939) in Ingelheim am Rhein. From its beginnings in 1885, when it employed just 28 people in Nieder-Ingelheim, it has since become a global enterprise. Day by day, the 50,000 employees of Boehringer Ingelheim create value through innovation with a clear goal is to provide more health and improve the lives of both humans and animals.
Product Portfolio: As part of research and development activities for innovative drugs, the company focuses primarily on the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology.
Boehringer Ingelheim- A Phase I/II Open-Label, Dose Escalation Trial to determine the MTD, safety, PK and Efficacy of Afatinib Monotherapy in Children Aged ≥1 Year to <18 Years with Recurrent/Refractory Neuroectodermal Tumours, Rhabdomyosarcoma is completed on March 2021.
The global Alveolar Rhabdomyosarcoma Treatment Market report would provide an access to an approx. 53 market data table, 47 figures and 240 pages.
LIST NOT EXHAUSTIVE